Preparation complexity
Ready-to-use aseptic presentations may reduce preparation and handling steps for suitable medicines.
Hovina is developing patented Blow Fill Insert Seal (BFIS) technology for large-volume, ready-to-use aseptic injectable medicines, with a focus on packaging innovation and manufacturing simplicity.

Drug shortages, medication preparation requirements, and manufacturing complexity create challenges across healthcare. Hovina is exploring how packaging technology for ready-to-use aseptic medicines could help address these needs.
Ready-to-use aseptic presentations may reduce preparation and handling steps for suitable medicines.
Packaging innovation may help manufacturers explore new ways to supply aseptic injectable medicines.
Hovina is developing BFIS for large-volume aseptic injectable applications, including heat-sensitive drug products.
BFIS is Hovina’s patented packaging technology platform under development for large-volume, ready-to-use aseptic injectable medicines, including heat-sensitive products.
The platform brings together container design and pharmaceutical manufacturing considerations. Product suitability and manufacturing performance depend on further development, evaluation, and validation.
Designed to support ready-to-use aseptic injectable products through a differentiated container and manufacturing approach.
High-level overview only. Detailed technical information is available through appropriate confidential discussions.
BFIS is being developed around three priorities for pharmaceutical manufacturers and healthcare users.
A packaging approach intended to simplify aspects of pharmaceutical manufacturing and support efficient production.
A platform designed with scalable development and future manufacturing needs in mind.
Ready-to-use aseptic medicines may reduce preparation steps for suitable formulations and support simpler administration workflows.
Based in Albany, New York, Hovina is developing BFIS technology for large-volume, ready-to-use aseptic injectable medicines. We welcome discussions with pharmaceutical manufacturers, development organizations and strategic partners interested in exploring potential applications and collaboration.
Hovina welcomes confidential discussions with pharmaceutical manufacturers, development partners, and organizations interested in evaluating BFIS technology, potential product applications, and strategic collaboration opportunities. Additional technical information may be shared under an appropriate confidentiality agreement.
jhover@hovina.life ↗Jeff Hover · Founder · Hovina Inc.